[
  {"doc_id":"F2020-AR-C007","type":"Annual Report","date":"2021-03-01","title":"2020 Annual Report","body":"VitalFlow Medical achieved FDA 510k clearance for its VitalPump Smart Infusion System, marking a key regulatory milestone. Revenue reached $72.3 million with improving gross margins as the company scaled manufacturing. Key risks include regulatory compliance complexity and competitive pressure from established medical device companies. The company invested heavily in R&D for next-generation patient monitoring solutions and expanded its clinical partnerships. ESG initiatives focus on patient safety, sustainable manufacturing practices, and healthcare access programs."},
  {"doc_id":"F2021-AR-C007","type":"Annual Report","date":"2022-02-28","title":"2021 Annual Report","body":"Revenue grew to $94.9 million driven by VitalPump commercial deployment and FlowSensor Monitor launch with Mayo Clinic. The company expanded its product portfolio and strengthened clinical evidence through prestigious hospital partnerships. Manufacturing capabilities were enhanced to meet growing demand. Management outlined strategic focus on integration solutions and AI-powered monitoring capabilities."},
  {"doc_id":"F2022-AR-C007","type":"Annual Report","date":"2023-02-27","title":"2022 Annual Report","body":"Strong revenue growth to $125.2 million was achieved through major hospital network deployments including Johns Hopkins. The MedConnect Integration Hub gained significant traction in the market. Investment in cybersecurity and data protection increased following healthcare sector threats. The company maintained focus on clinical outcomes and patient safety while scaling operations."},
  {"doc_id":"F2023-AR-C007","type":"Annual Report","date":"2024-02-28","title":"2023 Annual Report","body":"Revenue reached $143.4 million with the landmark VA Medical Centers contract providing long-term growth visibility. The company demonstrated strong execution in government healthcare sector while maintaining commercial momentum. Risk management processes were enhanced following increased regulatory scrutiny across the medical device industry."},
  {"doc_id":"F2024-AR-C007","type":"Annual Report","date":"2025-02-28","title":"2024 Annual Report","body":"Despite a safety incident requiring voluntary recall of 500 devices, the company maintained revenue at $158.6 million and successfully resolved FDA investigation. Enhanced safety protocols were implemented across all product lines. Strategic partnerships were formed to expand market reach and technological capabilities. The incident response demonstrated the company's commitment to patient safety and regulatory compliance."},
  {"doc_id":"ER-2025-08-C007","type":"Earnings Release","date":"2025-08-19","title":"Q2 2025 Earnings Release","body":"VitalFlow Medical reported strong Q2 2025 results with revenue of $41.8 million and EPS of $0.21, exceeding analyst expectations. Hospital adoption accelerated following successful resolution of 2024 safety incident. The company raised full-year guidance citing robust pipeline and strategic partnership momentum. Management emphasized continued focus on patient safety and innovation in medical device technology."},
  {"doc_id":"FDA-2020-04-C007","type":"FDA Clearance Letter","date":"2020-04-15","title":"510k Clearance - VitalPump System","body":"The Food and Drug Administration grants 510k clearance for the VitalPump Smart Infusion System following comprehensive safety and efficacy review. The device demonstrates substantial equivalence to existing infusion pump systems while providing enhanced safety features and connectivity capabilities."},
  {"doc_id":"INC-2024-03-C007","type":"Incident Report","date":"2024-03-14","title":"Voluntary Device Recall Notice","body":"VitalFlow Medical announces voluntary recall of 500 VitalPump devices due to software malfunction that could potentially affect medication delivery accuracy. The company is working closely with FDA and affected hospitals to ensure patient safety. Enhanced software testing protocols are being implemented to prevent similar issues."},
  {"doc_id":"RES-2024-07-C007","type":"Resolution Document","date":"2024-07-25","title":"FDA Investigation Resolution","body":"FDA investigation of VitalFlow Medical device recall has been completed with no regulatory action required. The company has implemented enhanced safety protocols including improved software testing, expanded quality assurance processes, and additional clinical monitoring capabilities. All affected devices have been successfully remediated or replaced."},
  {"doc_id":"PART-2025-02-C007","type":"Partnership Agreement","date":"2025-02-10","title":"Healthcare Technology Alliance Formation","body":"VitalFlow Medical announces strategic partnership with Medisafe Health and Borealis CloudWorks to create comprehensive healthcare technology solutions. The alliance combines medical device expertise with health data analytics and cloud infrastructure to deliver integrated patient care solutions. Initial focus areas include remote patient monitoring and predictive healthcare analytics."}
]
